Stock Target Advisor calculates key financial raios, of all the stocks in our database on a daily basis and then compares and ranks the financial ratios against those of other stocks in the same industries and exchanges. This allows our users to quickly determine how a stock is performing against its peers.
How do we grade Genmab AS (GMAB's) financial ratios?
Financial ratios do not impart much information on their own unless they are compared against the ratios of similar stocks. Every day we run millions of calculations to determine the pertinent ratios for each stock, and then we rank the stock against the stocks in the same exchange and sector for each ratio and assign a grade based on the percentile ranking based on the table below. Stock Target Advisor’s users can quickly determine where their favourite stocks stand by looking at their grades for key ratios.
Grade
Percentile
Grade
Percentile
Grade
Percentile
A+
97%-100%
A
93%-96%
A-
90%-92%
B+
87%-89%
B
83%-86%
B-
80%-82%
C+
77%-79%
C
73%-76%
C-
70%-72%
D+
67%-69%
D
63%-66%
D-
60%-62%
F
0%-59%
Frequently Asked Questions About (GMAB) Stock
The Price/Earnings ratio of Genmab AS stock as of 2024-11-21 is N/A versus its sectors median of . Compared to its peers, Genmab AS's Price/Earning ratio is in the N/A% which earns it a grade of N/A.
The current poor grade of Genmab AS's stock's Price to Earning ratio means that , it is trading well above the sector median. This means that it may be over priced and expensive. You may want to look at other ratios and analyst ratings to determine if it may still go up in price, otherwise, you should be cautious.
The Price/Book ratio of Genmab AS stock as of 2024-11-21 is N/A versus its sectors median of . Compared to its peers, Genmab AS's Price/Book ratio is in the N/A% which earns it a grade of N/A.
The current poor grade of Genmab AS's stock's Price to Book ratio means that , it is trading well above the sector median. This means that it may be over priced and expensive. You may want to look at other ratios and analyst ratings to determine if it may still go up in price, otherwise, you should be cautious.
The EV/EBITDA ratio of Genmab AS stock as of 2024-11-21 is N/A versus its sectors median of . Compared to its peers, Genmab AS's EV/EBITDA ratio is in the N/A% which earns it a grade of N/A.
The current poor grade of Genmab AS's stock's EV to EBITDA ratio means that , it is trading well above the sector median. This means that it may be over priced and expensive. You may want to look at other ratios and analyst ratings to determine if it may still go up in price, otherwise, you should be cautious.
The Return on Equity (ROE) of Genmab AS stock as of 2024-11-21 is N/A versus its sectors median of . The Return on Equity (ROE) for GMAB is calculated by dividing the company's net income by its shareholders' equity, essentially measuring how effectively the company uses the money invested by its shareholders to generate profits.
While historical ROE can provide insights into Genmab AS's past performance and efficiency in using shareholders' equity, it should not be solely relied upon to predict future performance. Future ROE can be influenced by a variety of factors such as changes in the company's management strategies, market conditions, competitive landscape, and overall economic environment. Therefore, investors should consider both historical performance and future prospects and risks when evaluating a stoc
Compared to its peers, Genmab AS's RoE is in the N/A% which earns it a grade of N/A.
The current poor grade of Genmab AS's stock's RoE signals less efficiency in using shareholders' equity to generate profits, potentially making it less attractive to investors seeking high-performing stocks within (Biotechnology). You may want to look at other ratios and analyst ratings to determine if it may still go up in price, otherwise, you should be cautious.
The Return on Invested Capital (ROIC) of Genmab AS stock as of 2024-11-21 is N/A versus its sectors median of . The ROIC (Return on Invested Capital) is calculated by dividing Genmab AS's net operating profit after taxes (NOPAT) by its total invested capital, which is the sum of shareholders' equity, debt, and any other long-term funding sources. A high ROIC indicates efficient capital use and effective management, often making the company an attractive investment.
Past ROIC is insightful but not a guaranteed predictor of future performance, as it can be influenced by market shifts and company changes; investors should assess both historical and potential future performance.
Compared to its peers, Genmab AS's RoIC is in the N/A% which earns it a grade of N/A.
The current poor grade of Genmab AS's stock's RoIC implies less effective use of invested capital in generating profits, potentially a red flag for investors prioritizing capital efficiency, but this should be balanced against the company's long-term growth potential and specific industry challenges.
The Return on Assets (ROA) of Genmab AS as of 2024-11-21 is compared to its sector's median of . ROA is calculated by dividing Genmab AS's net income by its total assets. A high ROA signifies efficient use of assets in generating profits, often making the company a compelling investment choice.
While past ROA offers insight, it's not a definitive indicator of future performance due to possible market and company changes; investors should consider both historical and anticipated performance.
Genmab AS's ROA is in the N/A% percentile, earning it a grade of N/A.
The lower grade of Genmab AS's ROA suggests less effective use of assets in profit generation, a concern for investors focused on asset efficiency, but it should be weighed against the company's growth potential and industry-specific factors.
The Debt to Equity Ratio of Genmab AS as of 2024-11-21 is N/A compared to the sector's average of . The D/E ratio is calculated by dividing Genmab AS's total liabilities by its shareholder equity. A lower D/E ratio suggests conservative debt usage and potentially lower financial risk.
Past D/E ratios offer insights but aren't absolute predictors of future stability; market conditions and company strategies change, so both historical and forward-looking analyses are important.
Genmab AS's D/E ratio is in the N/A% percentile, earning it a grade of N/A.
The lower grade for Genmab AS's D/E ratio implies higher reliance on debt, which could raise concerns for investors wary of high financial leverage, requiring careful assessment of the company’s financial strategies and industry context.
The Dividend Yield of Genmab AS as of 2024-11-21 is N/A compared to the sector's average of . Dividend Yield is calculated by dividing the annual dividends per share by the stock's current price. A higher dividend yield can be appealing to investors seeking regular income.
While past dividend yields can offer insights, they are not definitive indicators of future yields, as they can be influenced by stock price fluctuations and company dividend policies; both historical and future prospects should be considered.
Genmab AS's Dividend Yield ranks in the N/A% percentile, earning it a grade of N/A.
The lower grade for Genmab AS's Dividend Yield implies a lower yield compared to the industry, which may be less appealing to those seeking high dividend income, and should be assessed alongside the company's growth potential and dividend policy stability.
The Short Ratio of Genmab AS as of 2024-11-21 is N/A compared to the sector's average of . The Short Ratio is calculated by dividing the number of shares sold short by the stock's average daily trading volume. A lower Short Ratio suggests fewer investors are betting against the stock, potentially indicating market confidence.
Past Short Ratios can provide context but are not sole predictors of future sentiment, as market conditions and company performance can change; thus, both historical and future outlooks should be considered.
Genmab AS's Short Ratio ranks in the N/A% percentile, earning it a grade of N/A.
The lower grade for Genmab AS's Short Ratio implies higher short interest, potentially indicating market skepticism or bearish sentiment, which investors should balance against the company's long-term potential and industry factors.
The Short Percent of Float for Genmab AS as of 2024-11-21 is N/A compared to the sector's average of . The Short Percent of Float is calculated by dividing the number of shares shorted by the stock's floating shares. A lower Short Percent of Float suggests less bearish sentiment among investors, potentially indicating market confidence.
While historical Short Percent of Float provides some insight, it does not fully predict future market sentiment, as it can be influenced by changes in market conditions and company performance; thus, evaluating both past and projected trends is crucial.
Genmab AS's Short Percent of Float ranks in the N/A% percentile, receiving a grade of N/A.
The lower grade for Genmab AS's Short Percent of Float suggests higher short interest than its sector, possibly reflecting market skepticism or bearish sentiment, and investors should weigh this against the company's long-term growth potential and industry-specific factors.
The Beta value of Genmab AS as of 2024-11-21 is N/A compared to the industry average. Beta measures the stock's volatility relative to the overall market, with a lower Beta indicating less volatility and potentially lower risk.
While historical Beta offers insights, it's not a definitive predictor of future volatility, as market dynamics and company-specific factors can change; investors should consider both past trends and future market conditions.
Genmab AS's Beta ranks in the N/A% percentile, earning it a grade of N/A.
The lower grade for Genmab AS's Beta implies higher volatility compared to the market, which may concern risk-averse investors, and should be balanced against the company’s overall risk management and sector volatility.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GMAB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
